From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting candidates allowing once-monthly administration may become the next ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Energy equipment and services provider Flowco launched the year’s first major IPO, planning to raise $392 million and list in ...

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

The obesity market was a dominating force in 2024, with GLP-1 medications from Novo Nordisk and Eli Lilly becoming some of ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...